What are the clinical manifestations, electrophysiologic findings, and prognosis of copper‑deficiency myeloneuropathy, and how does the timing of copper supplementation affect recovery?

Copper Deficiency Myeloneuropathy: Clinical Features, Electrophysiology, and Treatment Outcomes

Copper deficiency myeloneuropathy presents with a characteristic triad: sensory ataxia from dorsal column dysfunction, spastic gait from corticospinal tract involvement, and peripheral neuropathy—essentially mimicking subacute combined degeneration from B12 deficiency 1.

Clinical Manifestations

The neurological presentation is remarkably consistent across patients:

• Gait disturbance is the dominant presenting symptom, reflecting sensory ataxia due to posterior column dysfunction combined with lower limb spasticity 1
• Subacute ascending paresthesias typically precede the gait disorder by weeks to months 2
• All patients develop polyneuropathy affecting the lower extremities 1
• Posterior cord syndrome is universal, manifesting as:
  • Loss of vibration and proprioception
  • Sensory ataxic gait
  • Superficial hypoesthesia of the feet
  • In 50% of cases, lateral cord signs (spasticity, hyperreflexia) 2

A critical diagnostic pitfall: time to diagnosis ranges from 2.5 to 15 months because this condition is frequently overlooked 2. The clinical picture is virtually indistinguishable from B12 deficiency myelopathy, so copper levels must be checked in any patient with suspected subacute combined degeneration.

Electrophysiologic Findings

Somatosensory evoked potentials (SSEPs) consistently show impaired conduction in central proprioceptive pathways 1. This finding is present in all tested patients and reflects dorsal column dysfunction.

Nerve conduction studies reveal axonal sensorimotor polyneuropathy in the majority of patients 2, 3. The peripheral nerve involvement is axonal rather than demyelinating, which helps distinguish this from inflammatory neuropathies like AIDP.

Imaging Characteristics

Spinal MRI findings are inconsistent and cannot rule out the diagnosis:

• Only 3 of 13 patients in one series showed dorsal column signal changes 1
• When present, T2 hyperintensity involves the posterior columns 3
• Normal MRI occurs in 43% of cases (3 of 7 patients) 2, so absence of imaging abnormalities should not dissuade you from the diagnosis

Advanced imaging with diffusion tensor imaging shows decreased fractional anisotropy in affected areas, which normalizes before clinical improvement 4.

Laboratory Confirmation

Serum copper is always low when symptomatic 2. Associated findings include:

• Low ceruloplasmin (often the initial clue) 1
• Anemia and lymphopenia in 86% of patients (6 of 7) 2
• High or high-normal serum zinc in 64% of cases (7 of 11) 1
• Urinary copper is low or normal 2

Prognosis and Treatment Timing

The harsh reality: copper supplementation prevents further deterioration but produces variable and often limited neurological improvement 1, 5. Here's what the evidence shows:

Recovery Timeline After Copper Supplementation:

1. Copper levels normalize first (within weeks)
2. Hematological abnormalities resolve within 2 months 2
3. MRI changes disappear by 10 months 2
4. Neurological improvement lags significantly behind biochemical and radiological recovery 4, 2

Degree of Neurological Recovery:

Most patients experience stabilization rather than meaningful improvement 5. In a series of 10 patients, copper supplementation led primarily to halting progression rather than reversing deficits.

However, earlier treatment appears to offer better outcomes: One patient who received copper supplementation 8 months after symptom onset achieved complete resolution of ataxia 3, while another case showed significant improvement when treated early 6. This contrasts with the generally poor recovery in patients diagnosed after 15 months of symptoms.

The critical window: initiate copper supplementation immediately upon diagnosis, as delayed treatment beyond 8-12 months may result in irreversible neurological damage 2, 3.

Supplementation Approach:

• Oral copper supplementation is first-line and restores normal copper levels in most patients (7 of 12 with adequate follow-up) 1
• Parenteral (IV) copper should be used when oral supplementation fails or in severe cases 1, 6
• Continue supplementation until copper levels normalize and stabilize

Common Etiologies to Investigate:

• Gastric/bariatric surgery with malabsorption 2, 7
• Excessive zinc intake (denture adhesives, supplements) 2, 8
• Malnutrition or parenteral nutrition 2
• Nephrotic syndrome 3
• Autoimmune conditions causing malabsorption 9

In many cases, no clear etiology is identified 1, but this should not delay treatment.